# EDGAR Filing Document

**Accession Number:** 0001761612
**File Stem:** 0000000000-25-008436
**Filing Date:** 2025-8
**Character Count:** 2533
**Document Hash:** 394ccf0f3b795b5e0478f9e70cdd4ec8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008436.hdr.sgml**: 20250912

**ACCESSION NUMBER**: 0000000000-25-008436

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250812

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BICYCLE THERAPEUTICS PLC
- **CENTRAL INDEX KEY:** 0001761612
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-289423

**BUSINESS ADDRESS:**
- **STREET 1:** BLOCKS A & B, PORTWAY BUILDING
- **STREET 2:** GRANTA PARK, GREAT ABINGTON
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB21 6GS
- **BUSINESS PHONE:** 011441223261503

**MAIL ADDRESS:**
- **STREET 1:** BLOCKS A & B, PORTWAY BUILDING
- **STREET 2:** GRANTA PARK, GREAT ABINGTON
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB21 6GS

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BICYCLE THERAPEUTICS plc
- **DATE OF NAME CHANGE:** 20190530

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BICYCLE THERAPEUTICS Ltd
- **DATE OF NAME CHANGE:** 20181212
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001104659-25-075684

## Text-Extract

```

                                                           August 12, 2025

Alethia Young
Chief Financial Officer
Bicycle Therapeutics plc
Blocks A & B, Portway Building
Granta Park Great Abington, Cambridge CB21 6GS
United Kingdom

       Re: Bicycle Therapeutics plc
           Registration Statement on Form S-3
           Filed August 8, 2025
           File No. 333-289423
Dear Alethia Young:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Jessica Dickerson at 202-551-8013 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Jaime L. Chase, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._